{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T13:38:36Z","timestamp":1777815516461,"version":"3.51.4"},"publisher-location":"Chichester, UK","reference-count":90,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd010692.pub2","type":"reference-entry","created":{"date-parts":[[2014,6,23]],"date-time":"2014-06-23T14:30:40Z","timestamp":1403533840000},"source":"Crossref","is-referenced-by-count":32,"title":["Oxycodone for neuropathic pain and fibromyalgia in adults"],"prefix":"10.1002","author":[{"given":"Helen","family":"Gaskell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R Andrew","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheena","family":"Derry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Stannard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,6,23]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD010692.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1212\/01.WNL.0000057720.36503.2C","article-title":"Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial","volume":"60","author":"Gimbel","year":"2003","journal-title":"Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD010692.pub2-BIB2|cit2","first-page":"71","article-title":"Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy","volume":"105","author":"Jensen","year":"2003","journal-title":"Pain"},{"issue":"6","key":"10.1002\/14651858.CD010692.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1212\/WNL.50.6.1837","article-title":"Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia","volume":"50","author":"Watson","year":"1998","journal-title":"Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD010692.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0304-3959(03)00160-X","article-title":"Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy","volume":"105","author":"Watson","year":"2003","journal-title":"Pain"},{"issue":"11","key":"10.1002\/14651858.CD010692.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1517\/14656566.2010.497720","article-title":"Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study","volume":"11","author":"Buynak","year":"2010","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000186502","article-title":"Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study","volume":"61","author":"Gatti","year":"2009","journal-title":"European Neurology"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00002508-199909000-00004","article-title":"Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain","volume":"15","author":"Hale","year":"1999","journal-title":"The Clinical Journal of Pain"},{"issue":"1","key":"10.1002\/14651858.CD010692.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jpain.2004.09.005","article-title":"Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study","volume":"6","author":"Hale","year":"2005","journal-title":"Journal of Pain"},{"issue":"6","key":"10.1002\/14651858.CD010692.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ejpain.2007.12.010","article-title":"Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients","volume":"12","author":"Hanna","year":"2008","journal-title":"European Journal of Pain"},{"issue":"7","key":"10.1002\/14651858.CD010692.pub2-BIB10|cit10","first-page":"623","article-title":"Analgesic effect of oxycodone-acetaminophen tablet in treatment of backleg pain [sic]","volume":"18","author":"He","year":"2009","journal-title":"Chinese Journal of New Drugs"},{"issue":"6","key":"10.1002\/14651858.CD010692.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12325-010-0036-3","article-title":"Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain","volume":"27","author":"Lange","year":"2010","journal-title":"Advances in Therapy"},{"issue":"4","key":"10.1002\/14651858.CD010692.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1517\/14656560902796798","article-title":"Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial","volume":"10","author":"L\u00f6wenstein","year":"2009","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"12","key":"10.1002\/14651858.CD010692.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1185\/03007990802584454","article-title":"Fixed-ratio combination oxycodone\/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain","volume":"24","author":"Simpson","year":"2008","journal-title":"Current Medical Research and Opinion"},{"issue":"11","key":"10.1002\/14651858.CD010692.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jpain.2011.06.003","article-title":"Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study","volume":"12","author":"Steiner","year":"2011","journal-title":"Journal of Pain"},{"issue":"12","key":"10.1002\/14651858.CD010692.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jpain.2006.05.005","article-title":"Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain","volume":"7","author":"Webster","year":"2006","journal-title":"Journal of Pain"},{"issue":"5","key":"10.1002\/14651858.CD010692.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1533-2500.2010.00397.x","article-title":"Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain","volume":"10","author":"Wild","year":"2010","journal-title":"Pain Practice"},{"issue":"39","key":"10.1002\/14651858.CD010692.pub2-BIB17|cit17","first-page":"45","article-title":"Controlled-release oxycodone -- a therapeutic option for severe neuropathic pain","volume":"145","author":"W\u00f6rz","year":"2003","journal-title":"MMW Fortschritte der Medizin"},{"issue":"5","key":"10.1002\/14651858.CD010692.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jpain.2009.09.003","article-title":"A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin","volume":"11","author":"Zin","year":"2010","journal-title":"Journal of Pain"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD010692.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.pain.2010.11.010","article-title":"Pain and the brain: specificity and plasticity of the brain in clinical chronic pain","volume":"152","author":"Apkarian","year":"2011","journal-title":"Pain"},{"issue":"9","key":"10.1002\/14651858.CD010692.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision","volume":"17","author":"Attal","year":"2010","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD010692.pub2-BIB21|cit21","unstructured":"PaPaS author and referee guidance http:\/\/papas.cochrane.org\/papas-documents (accessed 22 January 2013)"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.pain.2007.08.013","article-title":"Prevalence of chronic pain with neuropathic characteristics in the general population","volume":"136","author":"Bouhassira","year":"2008","journal-title":"Pain"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD010692.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.amjmed.2012.12.001","article-title":"The effect of opioid therapy on endocrine function","volume":"126","author":"Brennan","year":"2013","journal-title":"American Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010692.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jpain.2012.08.008","article-title":"Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment","volume":"14","author":"Butler","year":"2013","journal-title":"Journal of Pain"},{"issue":"9","key":"10.1002\/14651858.CD010692.pub2-BIB25|cit25","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010111","article-title":"Topical capsaicin (low concentration) for chronic neuropathic pain in adults","author":"Derry","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub2-BIB26|cit26","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007393.pub3","article-title":"Topical capsaicin (high concentration) for chronic neuropathic pain in adults","author":"Derry","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD010692.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1503\/cmaj.090784","article-title":"Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone","volume":"181","author":"Dhalla","year":"2009","journal-title":"Canadian Medical Association Journal"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2007.08.033","article-title":"Pharmacologic management of neuropathic pain: evidence-based recommendations.","volume":"132","author":"Dworkin","year":"2007","journal-title":"Pain"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"Journal of Pain"},{"issue":"1","key":"10.1002\/14651858.CD010692.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD010692.pub2-BIB31|cit31","first-page":"898493","article-title":"Opioid use in fibromyalgia is associated with negative health related measures in a prospective cohort study","author":"Fitzcharles","year":"2013","journal-title":"Pain Research and Treatments"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub2-BIB32|cit32","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002763.pub2","article-title":"Single dose oral oxycodone and oxycodone plus paracetamol (acetaminophen) for acute postoperative pain in adults","author":"Gaskell","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010692.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1399-6576.2007.01486.x","article-title":"Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey","volume":"52","author":"Gustorff","year":"2008","journal-title":"Acta Anaesthesiologica Scandinavica"},{"key":"10.1002\/14651858.CD010692.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2296-9-26","article-title":"Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005","volume":"9","author":"Hall","year":"2008","journal-title":"BMC Family Practice"},{"key":"10.1002\/14651858.CD010692.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2296-14-28","article-title":"An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population","volume":"14","author":"Hall","year":"2013","journal-title":"BMC Family Practice"},{"key":"10.1002\/14651858.CD010692.pub2-BIB36|cit36","unstructured":"Higgins JPT Green S editor(s) Chapter 8: Assessing risk of bias in included studies Higgins JPT Altman DG Sterne JAC Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration"},{"key":"10.1002\/14651858.CD010692.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1471-2474-13-74","article-title":"The German fibromyalgia consumer reports - a cross-sectional survey","volume":"13","author":"H\u00e4user","year":"2012","journal-title":"BMC Musculoskeletal Disorders"},{"issue":"1","key":"10.1002\/14651858.CD010692.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD010692.pub2-BIB39|cit39","doi-asserted-by":"crossref","unstructured":"Jensen TS Baron R Haanp\u00e4\u00e4 M Kalso E Loeser JD Rice AS A new definition of neuropathic pain Pain 2011 2204 5","DOI":"10.1016\/j.pain.2011.06.017"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub2-BIB40|cit40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pain.2007.09.027","article-title":"How different is oxycodone from morphine?","volume":"132","author":"Kalso","year":"2007","journal-title":"Pain"},{"key":"10.1002\/14651858.CD010692.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000110284","article-title":"Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota,1945-1984","volume":"10","author":"Katusic","year":"1991","journal-title":"Neuroepidemiology"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub2-BIB42|cit42","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004846.pub2","article-title":"Topical lidocaine for the treatment of postherpetic neuralgia","author":"Khaliq","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD010692.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/archinte.1996.00440060089011","article-title":"The importance of quality of primary studies in producing unbiased systematic reviews","volume":"156","author":"Khan","year":"1996","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub2-BIB44|cit44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5055\/jom.2013.0160","article-title":"Rationale and design of the Oxycodone Users Registry: a prospective, multicenter registry of patients with nonmalignant pain","volume":"9","author":"Kim","year":"2013","journal-title":"Journal of Opioid Management"},{"issue":"1-3","key":"10.1002\/14651858.CD010692.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pain.2009.08.023","article-title":"Incidence of facial pain in the general population","volume":"147","author":"Koopman","year":"2009","journal-title":"Pain"},{"key":"10.1002\/14651858.CD010692.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2377-11-55","article-title":"Fibromyalgia and neuropathic pain\uff0ddifferences and similarities: a comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia","volume":"11","author":"Koroschetz","year":"2011","journal-title":"BMC Neurology"},{"key":"10.1002\/14651858.CD010692.pub2-BIB47|cit47","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7326\/0003-4819-107-2-224","article-title":"Meta-analysis in clinical research","volume":"107","author":"L'Abb\u00e9","year":"1987","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010692.pub2-BIB48|cit48","doi-asserted-by":"crossref","first-page":"W","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010692.pub2-BIB49|cit49","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007115.pub3","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia","author":"Lunn","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010692.pub2-BIB50|cit50","first-page":"9","article-title":"The epidemiology of self-reported fibromyalgia in Canada","volume":"27","author":"McNally","year":"2006","journal-title":"Chronic Diseases in Canada"},{"issue":"8","key":"10.1002\/14651858.CD010692.pub2-BIB51|cit51","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006146.pub2","article-title":"Opioids for neuropathic pain","author":"McNicol","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010692.pub2-BIB52|cit52","volume-title":"An Evidence-Based Resource for Pain Relief","author":"McQuay","year":"1998"},{"key":"10.1002\/14651858.CD010692.pub2-BIB53|cit53","article-title":"Chronic pain","volume-title":"Health Care Needs Assessment","author":"McQuay","year":"2007"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010692.pub2-BIB54|cit54","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.neuroimage.2007.03.054","article-title":"Brain imaging of neuropathic pain","volume":"37","author":"Moisset","year":"2007","journal-title":"Neuroimaging"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub2-BIB55|cit55","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0304-3959(98)00140-7","article-title":"Size is everything\uff0dlarge amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects","volume":"78","author":"Moore","year":"1998","journal-title":"Pain"},{"key":"10.1002\/14651858.CD010692.pub2-BIB56|cit56","first-page":"15","article-title":"Managing potential publication bias","volume-title":"Systematic Reviews in Pain Research: Methodology Refined","author":"Moore","year":"2008"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub2-BIB57|cit57","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007076.pub2","article-title":"Pregabalin for acute and chronic pain in adults","author":"Moore","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub2-BIB58|cit58","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pain.2010.05.011","article-title":"\"Evidence\" in chronic pain\uff0destablishing best practice in the reporting of systematic reviews","volume":"150","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub2-BIB59|cit59","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.pain.2010.02.032","article-title":"Chronic low back pain analgesic studies--a methodological minefield","volume":"149","author":"Moore","journal-title":"Pain"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub2-BIB60|cit60","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/ard.2009.107805","article-title":"Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice","volume":"69","author":"Moore","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub2-BIB61|cit61","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.pain.2010.02.039","article-title":"Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain","volume":"149","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub2-BIB62|cit62","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.pain.2010.07.013","article-title":"Numbers-needed-to-treat analyses\uff0ddo timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials","volume":"151","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub2-BIB63|cit63","article-title":"Gabapentin for chronic neuropathic pain and fibromyalgia in adults","author":"Moore","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD010692.pub2-BIB64|cit64","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.pain.2010.11.030","article-title":"Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen\/paracetamol combinations after third molar extraction","volume":"152","author":"Moore","year":"2011","journal-title":"Pain"},{"issue":"6","key":"10.1002\/14651858.CD010692.pub2-BIB65|cit65","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/EJA.0b013e328343c569","article-title":"Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion","volume":"28","author":"Moore","year":"2011","journal-title":"European Journal of Anaesthesiology"},{"issue":"12","key":"10.1002\/14651858.CD010692.pub2-BIB66|cit66","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008242.pub2","article-title":"Amitriptyline for neuropathic pain and fibromyalgia in adults","author":"Moore","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub2-BIB67|cit67","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pain.2011.10.004","article-title":"Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses","volume":"153","author":"Moore","year":"2012","journal-title":"Pain"},{"key":"10.1002\/14651858.CD010692.pub2-BIB68|cit68","first-page":"Epub ahead of p","article-title":"The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain","volume":"March 6","author":"Moore","year":"2013","journal-title":"Pain Practice"},{"issue":"4","key":"10.1002\/14651858.CD010692.pub2-BIB69|cit69","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/anae.12148","article-title":"Pain measures and cut-offs\uff0d'no worse than mild pain' as a simple, universal outcome","volume":"68","author":"Moore","year":"2013","journal-title":"Anaesthesia"},{"key":"10.1002\/14651858.CD010692.pub2-BIB70|cit70","doi-asserted-by":"crossref","first-page":"f2690","DOI":"10.1136\/bmj.f2690","article-title":"Expect analgesic failure; pursue analgesic success","volume":"346","author":"Moore","year":"2013","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD010692.pub2-BIB71|cit71","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/j.1532-2149.2013.00341.x","article-title":"Duloxetine use in chronic painful conditions - individual patient data responder analysis","volume":"18","author":"Moore","year":"2014","journal-title":"European Journal of Pain"},{"key":"10.1002\/14651858.CD010692.pub2-BIB72|cit72","unstructured":"National Institute for Health and Clinical Excellence Neuropathic pain:the pharmacological management of neuropathic pain in adults in non-specialist settings www.nice.org.uk\/guidance\/CG173"},{"issue":"1","key":"10.1002\/14651858.CD010692.pub2-BIB73|cit73","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1526-4637.2009.00685.x","article-title":"Patient-centered perspective on treatment outcomes in chronic pain","volume":"11","author":"O'Brien","year":"2010","journal-title":"Pain Medicine"},{"issue":"11","key":"10.1002\/14651858.CD010692.pub2-BIB74|cit74","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.pain.2013.06.001","article-title":"Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia","volume":"154","author":"Oaklander","year":"2013","journal-title":"Pain"},{"issue":"4","key":"10.1002\/14651858.CD010692.pub2-BIB75|cit75","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/ACO.0b013e32832bc818","article-title":"Oxycodone: new 'old' drug","volume":"22","author":"Olkkola","year":"2009","journal-title":"Current Opinions in Anasesthesiology"},{"issue":"4","key":"10.1002\/14651858.CD010692.pub2-BIB76|cit76","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.tips.2013.02.001","article-title":"Does the pharmacology of oxycodone justify its increasing use as an analgesic?","volume":"34","author":"Olkkola","year":"2013","journal-title":"Trends in Pharmacological Sciences"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub2-BIB77|cit77","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0885-3924(93)90101-Z","article-title":"A review of oxycodone's clinical pharmacokinetics and pharmacodynamics","volume":"8","author":"Poyhia","year":"1993","journal-title":"Journal of Pain & Symptom Management"},{"key":"10.1002\/14651858.CD010692.pub2-BIB78|cit78","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0304-3959(94)90086-8","article-title":"Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion","volume":"56","author":"Rappaport","year":"1994","journal-title":"Pain"},{"key":"10.1002\/14651858.CD010692.pub2-BIB79|cit79","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012"},{"key":"10.1002\/14651858.CD010692.pub2-BIB80|cit80","first-page":"Epub ahead of p","article-title":"Neuropathic features of joint pain: a community-based study","volume":"April 1","author":"Soni","year":"2013","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD010692.pub2-BIB81|cit81","doi-asserted-by":"crossref","first-page":"f5108","DOI":"10.1136\/bmj.f5108","article-title":"Opioids in the UK: what\u2019s the problem?","volume":"347","author":"Stannard","year":"2013","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub2-BIB82|cit82","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2125.2008.03200.x","article-title":"Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review","volume":"66","author":"Straube","year":"2008","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD010692.pub2-BIB83|cit83","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2474-11-150","article-title":"Pregabalin in fibromyalgia\uff0dresponder analysis from individual patient data","volume":"11","author":"Straube","year":"2010","journal-title":"BMC Musculoskeletal Disorders"},{"key":"10.1002\/14651858.CD010692.pub2-BIB84|cit84","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2377-8-29","article-title":"Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials","volume":"8","author":"Sultan","year":"2008","journal-title":"BMC Neurology"},{"issue":"4","key":"10.1002\/14651858.CD010692.pub2-BIB85|cit85","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jpain.2005.11.008","article-title":"The epidemiology of chronic pain of predominantly neuropathic origin: results from a general population survey","volume":"7","author":"Torrance","year":"2006","journal-title":"Journal of Pain"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub2-BIB86|cit86","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrneurol.2011.4","article-title":"Can neuroimaging studies identify pain endophenotypes in humans?","volume":"7","author":"Tracey","year":"2011","journal-title":"Nature Reviews Neurology"},{"issue":"18","key":"10.1002\/14651858.CD010692.pub2-BIB87|cit87","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","article-title":"Neuropathic pain: redefinition and a grading system for clinical and research purposes","volume":"70","author":"Treede","year":"2008","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010692.pub2-BIB88|cit88","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330203","article-title":"The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD010692.pub2-BIB89|cit89","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.20140","article-title":"The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care and Research"},{"issue":"6","key":"10.1002\/14651858.CD010692.pub2-BIB90|cit90","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/brain\/awt053","article-title":"Small fibre pathology in patients with fibromyalgia syndrome","volume":"136","author":"\u00dc\u00e7eyler","year":"2013","journal-title":"Brain"}],"updated-by":[{"DOI":"10.1002\/14651858.cd010692.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T00:00:00Z","timestamp":1469664000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD010692.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:47:20Z","timestamp":1628549240000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD010692.pub2"}},"subtitle":[],"editor":[{"given":"Helen","family":"Gaskell","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,6,23]]},"references-count":90,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010692.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD010692.pub3","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2014,6,23]]}}}